Lab-on-a-Chip Systems in Therapeutic Drug Monitoring: From Microfluidics to Precision Medicine

The administration of pharmaceuticals is conventionally based on a "one-size-fits-all" paradigm, wherein dosing regimens are formulated from population averages derived during clinical trials. But this statistical average doesn't usually show what is really going on with a specific patient. Genetic polymorphisms in metabolizing enzymes (e.g., Cytochrome P450 isoenzymes), variations in body mass composition, organ function impairment (renal or hepatic), and concurrent medication use can result in significant inter-individual variability in drug absorption, distribution, metabolism, and excretion (ADME). [1]

This variability is clinically inconsequential for most drugs owing to an extensive therapeutic window. For a specific group of pharmacotherapeutic agents, though—those with a Narrow Therapeutic Index (NTI)—the difference between effectiveness and toxicity is very small. Therapeutic Drug Monitoring (TDM) is required in these situations. Therapeutic Drug Monitoring (TDM) is a clinical practice that involves measuring certain drugs at set times to keep their levels in a patient's blood steady. This helps to improve each patient's dosage regimen. [2]

TDM has always been a centralized process. Blood is taken from a vein, sent to a central lab, spun in a centrifuge to get plasma or serum, and then tested with expensive machines like High- Performance Liquid Chromatography (HPLC) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). These methods are very sensitive and specific, but they have some big problems: they are expensive to run, need large sample volumes (mL), and take a long time to get results (TAT), from 24 to 72 hours. This delay makes it so that doctors have to make dosing decisions based on estimates instead of real-time data, which could put patients at risk of not getting the right amount of medicine or getting too much. [3,4]

The arrival of Micro Total Analysis Systems (μTAS), also called Lab-on-a-Chip (LOC), marks a big change. LOC devices shrink laboratory operations down to the size of a chip. They move fluids in the nano- to microliter range, which cuts down on the amount of reagents needed and the time it takes to analyze them. The combination of these microfluidic platforms with very sensitive biosensors—devices that turn a biological recognition event into a measurable signal—could bring TDM to the Point-of-Care (POC). This review looks at how these technologies are coming together, focusing on the materials, mechanisms, and medical uses that make this new era of monitoring possible. [5]

Theoretical Framework of Microfluidics

To understand the potential of LOC for TDM, one must first appreciate the physics governing fluid behavior at the microscale.

Fluid Dynamics at the Microscale

The way fluids act in microchannels is very different from how they act on a larger scale. The Reynolds number ($Re$), which is the ratio of inertial forces to viscous forces, is the main dimensionless quantity that controls this behavior. In microfluidic channels, the Reynolds number ($Re$) is usually very low ($Re \ll 1$), which causes laminar flow.

Implications for TDM:

When fluids flow in laminar flow, they do so in parallel streams without any turbulence. Diffusion is the only way to mix things, and it takes a long time. To make sure that the blood sample mixes well with the reagents before it gets to the sensor, TDM chips must have special "micromixers," like herringbone structures. [7]

Surface Tension:

When the surface area to volume ratio gets bigger, surface tension becomes the most important force. In "passive" microfluidics, capillary action moves blood through a device without the need for external pumps. This is a key feature for handheld TDM devices.[8]

Materials and Fabrication

The choice of material dictates the chip’s cost, optical properties, and compatibility with biological samples.

Polydimethylsiloxane (PDMS):

The most common material for academic prototyping because soft lithography is easy to use. PDMS lets light through and lets gas through. But it has a big problem when it comes to drug monitoring: it is a hydrophobic sponge that absorbs small hydrophobic drug molecules, which could make drug concentration seem lower than it really is. [9]

Thermoplastics (PMMA/Polycarbonate):

Commercial devices are better off with these hard plastics. They don't absorb drugs, can be made in large quantities using injection molding, and have great optical clarity for fluorescence detection. [10]

Paper:

Paper-based microfluidics ($\mu$PADs) are at the very low end of the price range. These devices use patterned hydrophobic wax barriers to move fluids through capillary action. They are less sensitive, but they are perfect for places with few resources. [11]

Table 1: Comparison of Substrate Materials for LOC-TDM Devices [12,13,14,15]

Biosensing Mechanisms in Loc

The "heart" of the LOC device is the biosensor. For TDM, the sensor must distinguish the specific drug molecule from a soup of plasma proteins, metabolites, and other medications.

Electrochemical Transduction

Electrochemical sensors are the dominant modality in LOC-TDM due to their miniaturization potential, low power requirements, and compatibility with opaque samples like whole blood. Amperometry: This method checks the current that comes from the oxidation or reduction of an electroactive species at a steady voltage. It works very well for drugs that are naturally electroactive, like acetaminophen or some chemotherapeutics. [16]

Voltammetry:

Differential Pulse Voltammetry (DPV) and Square Wave Voltammetry (SWV) are two methods that use a dynamic potential sweep. This makes it possible to find several drugs at once (multiplexing) by separating their oxidation peaks at different voltages.[17] Electrochemical Impedance Spectroscopy (EIS): EIS checks the sensor surface's resistance and capacitance. It is often used in "label-free" detection, where a drug binds to an antibody on the electrode, stopping electron transfer and raising impedance. This is very important for finding big biologic drugs. [18]

Optical Transduction

Optical sensors generally offer higher sensitivity but require more complex instrumentation (light sources, detectors).

Surface Plasmon Resonance (SPR):

SPR can tell when the refractive index changes near a metal surface, which is usually gold. The angle of least light reflection changes when drug molecules attach to receptors on the gold surface. LOC devices that use "nanoplasmonics" (LSPR) use gold nanoparticles to do this without heavy prisms, making it possible to monitor protein-drug interactions on the go. [19]

Surface-Enhanced Raman Scattering (SERS):

Raman spectroscopy gives a molecular "fingerprint" by looking at how molecules vibrate. When drug molecules stick to rough metal surfaces like silver or gold nanostars, the Raman signal gets stronger by a factor. This lets you find drugs even in complicated liquids like saliva. [20]

Biorecognition Elements

The specificity of the sensor depends on the molecule used to "capture" the drug.

Enzymes: Enzymes are less common for drugs than they are for glucose, unless the drug is a substrate for a specific enzyme, like Methotrexate and Dihydrofolate Reductase. [21] Antibodies: The best way to be specific. But antibodies are costly, unstable at room temperature, and easily denatured, which shortens the shelf life of LOC devices. [22] Aptamers: These are synthetic single-stranded DNA or RNA sequences that have been chosen to stick to a certain target. Aptamers are the future of TDM sensors because they are cheap to make, can be reused, and are stable at high temperatures. [23]

1.         Sample Preparation Strategies On Chip

One of the most significant barriers to POC TDM is the sample matrix. Blood is a non- Newtonian fluid rich in cells and proteins that foul sensors.

Plasma Separation

Most TDM therapeutic ranges are defined for plasma concentration, not whole blood. Therefore, the chip must filter out Red Blood Cells (RBCs).

Inertial Microfluidics:

By making channels with certain curves, lift forces can move larger RBCs to one side of the channel while plasma flows to the other. This separates the two without using filters. [24]

Trench Structures:

Trench Structures: Cells can get stuck in simple physical barriers called "weirs," but plasma can still get through. But these can get clogged (haemolysis), which can let out intracellular contents and ruin the test. [25]

The Biofouling Challenge

When blood touches a sensor, proteins like albumin and fibrinogen quickly stick to the surface,

 creating a "protein corona." This layer keeps the sensor from interacting with the drug, which causes the signal to drift.

Solution:

To fix this, LOC devices use antifouling coatings like zwitterionic polymers or polyethylene glycol (PEG). These hydrophilic layers make a hydration shell that keeps proteins from sticking, which makes the sensor last longer. [26]

Clinical Applications And Therapeutic Classes

The integration of LOC and biosensors has reached distinct levels of maturity across different drug classes.

Antibiotics: Combating Resistance and Toxicity

TDM of antibiotics is essential in two situations: preventing toxicity (e.g., Aminoglycosides, Vancomycin) and guaranteeing efficacy in critically ill patients with modified clearance (e.g., Beta-lactams).

Vancomycin:

It is used to treat MRSA infections, but it has a high risk of nephrotoxicity. Gowers et al. created a biosensor that uses microneedles to sit on the skin and keep an eye on Vancomycin in Interstitial Fluid (ISF) all the time. The device employs an aptamer-based electrochemical detection technique, exhibiting a latency of merely 10 minutes in relation to blood concentrations. [27]

Aminoglycosides:

Recent research has concentrated on quantifying Gentamicin levels. A paper-based microfluidic device employing a colorimetric assay has been validated, enabling a "Red/Green" safety readout for nurses in resource-limited environments. [28]

Beta-Lactams:

These drugs break down quickly, which makes central lab analysis unreliable. Integrated LOC devices that measure beta-lactamase activity have been made to measure the concentration of unbound (active) drugs in real time. This helps doctors decide how much medicine to give patients with septic shock. [29]

Antineoplastic Agents: Precision Oncology

Chemotherapy drugs have narrow windows and high toxicity.

Doxorubicin:

An anthracycline antibiotic that is used to treat cancer. It is electroactive, which means that it can be directly detected. Saghary et al. used Single-Walled Carbon Nanotubes (SWCNTs) in a microfluidic channel to find Doxorubicin in serum. The nanotubes made it easier for electrons to move, which led to a Limit of Detection (LOD) of 0.6 nM, which is well below the toxic level. [30]

Methotrexate (MTX):

Utilized in elevated dosages for leukemia. Leucovorin "rescue" therapyis needed for toxicity based on MTX levels. Integrated SPR sensors have been created to keep track of how quickly MTX is being removed from the body in real time, which could shorten hospital stays. [31]

5-Fluorouracil (5-FU):

Genetic differences in the DPD enzyme can cause deadly 5-FU toxicity. A microfluidic chip that uses molecularly imprinted polymers (MIPs), which are plastic "molds" of the drug molecule, has been successfully tested for specific 5-FU detection in plasma. [32]

Immunosuppressants: Protecting the Graft

Post-transplant patients require lifelong TDM of drugs like Tacrolimus, Cyclosporine, and Sirolimus to prevent organ rejection.

The RBC Problem:

These drugs bind heavily to erythrocytes. A standard plasma chip will not work.

LOC Solution:

Engineers have used centrifugal forces to make automated "Lab-on-a-Disc" systems. The disc spins to separate the blood, mixes it with a lysis buffer to break the cells and release the drug, and then moves the sample to a chamber where it can be detected. This makes a four-hour lab process take only thirty minutes. [33]

Antiepileptics: Seizure Control

Phenytoin and Valproic Acid:

It is very important to keep things stable. The ultimate goal is to monitor people at home because they will probably have to take these drugs for the rest of their lives. Recent advancements encompass smartphone-integrated lateral flow assays (a fundamental type of LOC) that utilize the phone's camera to measure drug concentrations from a blood sample. [34]

Levetiracetam:

Researchers are making micro-cantilever sensors (mechanical detection) that bend when a drug sticks to the surface. Optical measurement of the amount of bending provides a label-free way to find this antiepileptic drug, which is becoming more common.[35]

Table 2: Key LOC-Biosensor Studies and Performance Metrics